Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > phase one

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Mar 29, 2022 3:12pm

69 Views

Post# 34556412

RE:phase one

polo22 wrote: hey Mr Bailey....are we gonne see something.this week ..easy to be negative. we need somme press release....

Everything is now in the hands of the ethics committee to make a decision, there is nothing Bob or anyone at Claritas to speed things up. Frustrating for them all, they were expecting a decision last week and now expecting this week. Hopefully not delayed much longer.

As for the B warrants, with each passing week they seem less likely to be of any value.

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project